Today: 21 May 2026
Browse Category

NYSE:JNJ 5 January 2026 - 16 January 2026

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares rose 2.3% to $218.55 in after-hours trading Wednesday after reporting its Tecvayli drug cut the risk of disease progression or death by 71% in a late-stage multiple myeloma trial. An independent committee recommended unblinding the study. Full results will be presented at an upcoming medical meeting. Investors await the company’s quarterly results next week.
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson shares rose 1.9% to $213.65 Tuesday and held steady after hours as Delaware’s top court ordered a recalculation of a $1 billion damages award tied to the Auris Health acquisition. The ruling could reduce the payout by several hundred million dollars. Investors are watching for J&J’s fourth-quarter results on Jan. 21 and updates from healthcare conferences this week.
14 January 2026
··
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares rose 1.6% to $212.98 Tuesday, outperforming a dip in healthcare stocks. Delaware’s Supreme Court ordered a recalculation of part of a $1 billion damages award tied to the Auris acquisition, which could reduce the payout by hundreds of millions. Legal developments and upcoming drug trial data are in focus ahead of the company’s Jan. 21 earnings call.
13 January 2026
···
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson shares fell 0.7% to $204.39 after announcing a deal with the Trump administration to cut U.S. drug prices in exchange for tariff exemptions. The company will offer some medicines at discounted rates via TrumpRx.gov but did not specify drugs or discount sizes. J&J also unveiled plans for two new U.S. manufacturing plants. Early trial data for its cancer drug amivantamab showed a 70% response rate in a first-line subgroup.
11 January 2026
··
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson shares fell 0.7% to $204.39 Friday after the company agreed to lower U.S. drug prices in exchange for tariff exemptions, with terms undisclosed. J&J will join the TrumpRx.gov platform and said it plans two new U.S. manufacturing sites. The S&P 500 rose 0.65%. Investors await the JPMorgan healthcare conference and J&J’s Jan. 21 earnings call.
10 January 2026
··
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
10 January 2026
····
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson shares rose 0.5% to $205.41 midday Tuesday after reporting positive Phase 2b results for its lupus drug nipocalimab and announcing plans for Phase 3 trials. The company also filed in Europe to expand use of its myeloma drug combo Tecvayli and Darzalex. J&J continues to face pressure from ongoing talc litigation, with more trials expected this year.
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson shares fell 1.47% to $204.31 Monday, underperforming the S&P 500’s 0.64% gain. UBS reiterated a Buy rating but lowered earnings forecasts after management warned of about $0.20 adjusted EPS dilution from the Halda Therapeutics acquisition. J&J will present at the JPMorgan Healthcare Conference Jan. 12 and report Q4 results Jan. 21.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
1 2 3 4 5 6 … 8

Stock Market Today

  • Planet Labs Nears Sustainable Profitability Amid Industry Challenges
    May 21, 2026, 3:12 PM EDT. Planet Labs (PL) operates a vast network of Earth observation satellites capturing global images daily. Despite technological advances and expanded roles in defense and agriculture, the company has yet to secure steady profits due to high costs in satellite manufacturing, launches, maintenance, and R&D. Revenue growth lags behind fixed costs, while long government sales cycles delay cash flow. Management's 2026 guidance shows optimism, focusing on cost control, vertical specialization, and software monetization to enhance margins. Industry peers Rocket Lab (RKLB) and BlackSky Technology (BKSY) face similar profitability challenges. PL's stock has surged 117% year-to-date but trades at a lofty price-to-sales ratio of 31.38, far above the industry average of 3.86, reflecting high investor expectations amid ongoing financial pressures.

Latest articles

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

21 May 2026
Nebius Group N.V. shares surged 15.6% to $221.72 after announcing a fuel cell power deal with Bloom Energy, securing up to 328 MW of on-site electricity capacity for its AI infrastructure. The agreement could cost Nebius up to $2.6 billion over 10 years. Bloom shares rose 12.2% on the news. Nebius's first-quarter revenue jumped to $399 million from $50.9 million a year earlier.
Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
Go toTop